


## WHAT IS CLAIMED IS:

1. A compound according to Formula I:



5 wherein:

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is independently 0, 1, 2, 3 or 4; p is 1 or 2; q is 0 or 1;

10 R¹ is selected from: H, halogen, (C₁-C₆)alkyl, OH, oxo, CN, (C₁-C₆)alkyl hydroxyl, NH₂ and O(C₁-C₆)alkyl;

R² is H or halogen;

15 R³ and R⁴ are independently selected from: H, CF₃, oxo, OH, halogen, CN, NH₂, NO₂, (C=O)ₐOᵇ(C₁-C₁₀)alkyl, (C=O)ₐOᵇ(C₂-C₁₀)alkenyl, (C=O)ₐOᵇ(C₂-C₁₀)alkynyl, (C=O)ₐOᵇ(C₃-C₆)cycloalkyl, (C=O)ₐOᵇ(C₀-C₆)alkylene-aryl, (C=O)ₐOᵇ(C₀-C₆)alkylene-heterocyclyl, (C=O)ₐOᵇ(C₀-C₆)alkylene-N(Rᵇ)₂, Oᵇ(C₁-C₃)perfluoroalkyl, (C₀-C₆)alkylene-S(O)ₘRᵃ, C(O)Rᵃ, (C₀-C₆)alkylene-CO₂Rᵃ, C(O)H, (C₀-C₆)alkylene-CO₂H, C(O)N(Rᵇ)₂, and S(O)₂N(Rᵇ)₂; said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from Rᵇ;

20

R⁵ is H or (C₁-C₆)alkyl;

25 Rᵃ is selected from: (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl and heterocyclyl; said alkyl, cycloalkyl, aryl and heterocyclyl is optionally substituted with one or more substituents selected from OH, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halogen, CO₂H, CN, (O)C=O(C₁-C₆)alkyl, oxo and N(Rᶜ)₂;

Rᵇ is independently selected from: H, oxo, OH, halogen, CO₂H, CN, (O)C=O(C₁-C₆)alkyl, N(Rᶜ)₂, (C₁-C₆)alkyl, aryl, heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)O(C₁-C₆)alkyl, C=O(C₁-C₆)alkyl and

$S(O)_2R^a$ ; said alkyl, cycloalkyl, aryl or heterocyclyl is optionally substituted with one or more substituents selected from OH,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, halogen,  $CO_2H$ , CN,  $(O)C=O(C_1-C_6)$ alkyl, oxo,  $N(R^c)_2$  and optionally substituted heterocyclyl, wherein said heterocyclyl is optionally substituted with  $(C_1-C_6)$ alkyl, oxo or  $NH_2$ .


5

$R^c$  is independently selected from: H and  $(C_1-C_6)$ alkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

10

2. The compound according to Claim 1 of the Formula II:




wherein all other substituents and variables are as defined in Claim 1;

or a pharmaceutically acceptable salt or stereoisomer thereof.

15

3. The compound according to Claim 2 of the Formula III;



wherein:

20

$R^1$  is selected from: H, F and OH;

$R^3$  is selected from: H,  $(C_1-C_6)$ alkyl,  $(C_3-C_6)$ cycloalkyl,  $(C_2-C_6)$ alkenyl and  $(C_1-C_6)$ alkyl hydroxyl;

R<sup>5</sup> is H or CH<sub>3</sub>;

and all other substituents and variables are as defined in Claim 2;

5 or a pharmaceutically acceptable salt or stereoisomer thereof.

4. The compound according to Claim 3 of the Formula III;

wherein:

10

R<sup>4</sup> is selected from: H, oxo, OH, halo, CN, NH<sub>2</sub>, NO<sub>2</sub>, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>, C(O)H, (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H, C(O)N(R<sup>b</sup>)<sub>2</sub>, and S(O)<sub>2</sub>N(R<sup>b</sup>)<sub>2</sub>; said alkyl, alkenyl, alkynyl, cycloalkyl, aryl,

15 alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>;

and all other substituents and variables are as defined in Claim 3;

or a pharmaceutically acceptable salt or stereoisomer thereof.

20

5. The compound according to Claim 3 of the Formula III;

wherein:

25

R<sup>4</sup> is selected from: H, oxo, OH, halo, CN, NH<sub>2</sub>, NO<sub>2</sub>, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C=O)<sub>a</sub>O<sub>b</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>, (C=O)-R<sup>b</sup>, C(O)H, (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H, C(O)N(R<sup>b</sup>)<sub>2</sub>, and S(O)<sub>2</sub>N(R<sup>b</sup>)<sub>2</sub>; said alkyl, alkenyl, alkynyl and alkylene is optionally substituted with up to three substituents selected from R<sup>b</sup>;

30

and all other substituents and variables are as defined in Claim 3;

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. A compound which is selected from:

35

- 3-[[3-(3-chloro-4-fluorophenyl)(2-hydroxy-1-methylethyl)amino]methyl]phenol;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]propan-1-ol;  
 N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1-[2(dimethylamino)ethyl] alaninamide;  
 N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)alaninamide;  
 5 methyl N-benzyl-N-(3-chloro-4-fluorophenyl)alanyl glycinate;  
 N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1-(isoxazol-4-ylmethyl)alaninamide;  
 3-[benzyl(3-chloro-4-fluorophenyl)amino]-2-methylbutan-2-ol;  
 N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1,N-1-dimethylpropane-1,2-diamine;  
 N-benzyl-3-chloro-4-fluoro-N-[1-methyl-2-(4-methylpiperazin-1-yl)ethyl]aniline;  
 10 2-[(3-chloro-4-fluorophenyl)(1-phenylethyl)amino]propan-1-ol;  
 N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)-N-1-(isoxazol-4-ylmethyl)alaninamide;  
 N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)alaninamide;  
 N-2-(3-chloro-4-fluorophenyl)-N-1-[2-(dimethylamino)ethyl]-N-2-(3-hydroxybenzyl)alaninamide;  
 Methyl 2-[benzyl(3-chloro-4-fluorophenyl)amino]butanoate;  
 15 Methyl 2-[benzyl(3-chloro-4-fluorophenyl)amino]pent-4-enoate;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]pent-4-en-1-ol;  
 N-benzyl-N-(3-chloro-4-fluorophenyl)glycine;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]pentan-1-ol;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]butan-1-ol;  
 20 N-benzyl-3-chloro-N-[1-({3-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)propyl]-4-fluoroaniline;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]-N-methyl-N-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]butanamide;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]-3-methylbutan-1-ol;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]pentane-1,5-diol;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]-3-cyclopropylpropan-1-ol; and  
 25 N<sup>2</sup>-benzyl-N<sup>2</sup>-(3-chloro-4-fluorophenyl)-N<sup>1</sup>-[2-(dimethylamino)ethyl]-2-methylalaninamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

7. The TFA salt of a compound according to Claim 1 which is
- 30 3-[[3-(3-chloro-4-fluorophenyl)(2-hydroxy-1-methylethyl)amino]methyl]phenol;  
 2-[benzyl(3-chloro-4-fluorophenyl)amino]propan-1-ol;  
 N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1-[2(dimethylamino)ethyl] alaninamide;  
 N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)alaninamide;  
 methyl N-benzyl-N-(3-chloro-4-fluorophenyl)alanyl glycinate;  
 35 3-[benzyl(3-chloro-4-fluorophenyl)amino]-2-methylbutan-2-ol;

2-[(3-chloro-4-fluorophenyl)(1-phenylethyl)amino]propan-1-ol;  
N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)-N-1-(isoxazol-4-ylmethyl)alaninamide;  
N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)alaninamide;  
N-2-(3-chloro-4-fluorophenyl)-N-1-[2-(dimethylamino)ethyl]-N-2-(3-hydroxybenzyl)alaninamide;  
5 N-benzyl-N-(3-chloro-4-fluorophenyl)glycine;  
2-[benzyl(3-chloro-4-fluorophenyl)amino]pentan-1-ol;  
2-[benzyl(3-chloro-4-fluorophenyl)amino]butan-1-ol;  
N-benzyl-3-chloro-N-[1-({3-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)propyl]-4-fluoroaniline;  
2-[benzyl(3-chloro-4-fluorophenyl)amino]-N-methyl-N-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]butanamide;  
10 2-[benzyl(3-chloro-4-fluorophenyl)amino]pentane-1,5-diol; and  
N<sup>2</sup>-benzyl-N<sup>2</sup>-(3-chloro-4-fluorophenyl)-N<sup>1</sup>-[2-(dimethylamino)ethyl]-2-methylalaninamide;

or stereoisomer thereof.

15 8. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

9. The use of the compound according to Claim 1 for the preparation of a medicament useful in the treatment or prevention of cancer in a mammal in need of such treatment.

20